ICON Gains MHRA Accreditation

ICON’s hospital-based Clinical Pharmacology Unit in Manchester, UK has achieved Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA). The unit is part of the ICON Development Solutions division. The designation allows the company to carry out all Phase I trials, including First in Human (FIH) trials requiring review from the EAG (Expert Advisory Group).

Thomas Frey, president of ICON Development Solutions, commented, “Our Clinical Pharmacology team in Manchester worked closely with the MHRA during their routine inspection to demonstrate our active commitment to safety and quality. This accreditation award, combined with our experience conducting more than 1,500 early phase studies, reinforces to trial volunteers and sponsors alike that ICON is an industry-leader in Phase I clinical research. We are pleased to have participated in this voluntary accreditation process that ensures continuous safety improvements are realized in early clinical development.”

The MHRA established this accreditation in 2006 to formalize routine, rigorous inspections, raising the level of clinical safety standards. The accreditation was granted following a successful MHRA GCP inspection of personnel and facilities, as well as the ability to manage medical emergencies.